Results 181 to 190 of about 26,203 (316)

Exploring EEG Spectral Patterns in Episodic and Chronic Migraine During the Interictal State: Determining Frequencies of Interest in the Resting State [PDF]

open access: bronze, 2020
Javier Gómez‐Pilar   +4 more
openalex   +1 more source

Effectiveness and safety of erenumab and galcanezumab in the prevention of chronic and episodic migraine: a retrospective cohort study [PDF]

open access: gold, 2021
Adrián Viudez‐Martínez   +4 more
openalex   +1 more source

Real‐world effectiveness and safety of galcanezumab for the treatment of migraine: A systematic review and meta‐analysis

open access: yesHeadache: The Journal of Head and Face Pain, Volume 66, Issue 1, Page 262-277, January 2026.
Abstract Objective This study aimed to summarize and pool real‐world evidence on the clinical effectiveness and safety of galcanezumab. Background Migraine is a disabling primary headache disorder. Several drugs that target calcitonin gene‐related peptide, such as galcanezumab, have recently been developed.
Jaime Fernández‐Bravo‐Rodrigo   +7 more
wiley   +1 more source

The Association of Obesity With Episodic and Chronic Migraine

open access: green, 2012
Randolph W. Evans   +3 more
openalex   +2 more sources

Engagement and predictors of use of a smartphone app for migraine self‐management: A secondary analysis of the EMMA trial

open access: yesHeadache: The Journal of Head and Face Pain, Volume 66, Issue 1, Page 118-131, January 2026.
Abstract Objective The objective of this secondary analysis was to examine engagement with a mobile app for migraine self‐management and to identify predictors of migraine app usage. Background Migraine self‐monitoring and behavioral strategies are central components in migraine self‐management, but patient adherence often remains a challenge. Recently,
Stefanie Lysk   +4 more
wiley   +1 more source

False nonresponders to anti‐calcitonin gene‐related peptide monoclonal antibodies: A real‐world analysis beyond migraine frequency reduction

open access: yesHeadache: The Journal of Head and Face Pain, Volume 66, Issue 1, Page 172-182, January 2026.
Abstract Objectives/Background Reimbursement criteria for anti‐calcitonin gene‐related peptide (CGRP) monoclonal antibodies (MAbs) typically rely on predefined reductions in monthly migraine days (MMD). However, this approach may fail to capture the full spectrum of treatment benefits, potentially leading to premature discontinuation in patients ...
Albert Muñoz‐Vendrell   +7 more
wiley   +1 more source

Topiramate for the prophylaxis of episodic migraine in adults

open access: green, 2013
Mattias Linde   +3 more
openalex   +2 more sources

Gamma-aminobutyric acid and glutamate/glutamine levels in the dentate nucleus and periaqueductal gray with episodic and chronic migraine: a proton magnetic resonance spectroscopy study [PDF]

open access: gold, 2022
Wei Wang   +11 more
openalex   +1 more source

Response to the Letter to the Editor: “Reaffirming Caution—The Unacceptable Vasoconstrictive Risk of CGRP‐Related Therapies in Moyamoya Angiopathy”

open access: yes
European Journal of Neurology, Volume 33, Issue 1, January 2026.
Nicola Rifino   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy